Guide to Tremfya and Advances in Psoriasis Treatment Research

Psoriasis is a chronic immune-mediated skin condition that causes inflammation, scaling, redness, and raised skin patches. Treatment developments increasingly focus on specific immune system pathways responsible for inflammation. Tremfya is one such targeted biologic treatment. Its active ingredient, guselkumab, belongs to a group of medicines called interleukin-23 (IL-23) inhibitors. It is designed to reduce inflammatory activity associated with psoriasis and improve skin symptoms. Ongoing clinical research continues to examine its effectiveness, long-term outcomes, and potential applications across different patient populations.

Understanding Tremfya and Its Role in Psoriasis Treatment

Tremfya works by targeting interleukin-23, a naturally occurring protein involved in immune system activity and inflammation. Guselkumab selectively binds to the p19 subunit of IL-23, preventing it from interacting with its receptor. This action helps reduce inflammatory signals associated with psoriasis.

The medication is approved in the United States for moderate-to-severe plaque psoriasis in eligible adults and certain children aged six years and older who weigh at least 40 kg. It is also approved for active psoriatic arthritis and certain inflammatory bowel conditions.

Important aspects of Tremfya treatment include:

  • Targeted immune action: It blocks IL-23 activity involved in inflammatory responses associated with psoriasis.

  • Administration schedule: For plaque psoriasis, the standard adult dose is 100 mg through subcutaneous injection at weeks zero and four, followed by injections every eight weeks.

  • Treatment eligibility: It is generally considered for patients who require systemic treatment or phototherapy.

  • Treatment monitoring: Healthcare professionals evaluate infection risks, medical history, and other relevant health factors before and during treatment.

  • Possible side effects: Common reactions include upper respiratory infections, headache, joint pain, diarrhea, and injection-site reactions.

Patients should be evaluated for tuberculosis before starting treatment. Live vaccines should be avoided during treatment, and active infections require appropriate medical assessment.

Advances in Psoriasis Treatment Research and Clinical Developments

Research into guselkumab continues to explore improvements in skin clearance, symptom management, and long-term disease control. Clinical trials are also examining treatment outcomes among people with different skin tones and patients experiencing psoriasis in difficult-to-treat body areas.

The VISIBLE clinical trial investigated guselkumab in participants with moderate-to-severe plaque psoriasis across different skin tones. Results published in 2025 showed that approximately 70% of participants achieved clear or almost clear skin by week 48. More than half achieved complete skin clearance, demonstrating encouraging treatment outcomes in the studied population.

Other research developments include:

  • High-impact skin areas: The SPECTREM clinical trial examined guselkumab in patients with psoriasis affecting areas such as the scalp, face, and other sensitive body regions. Results demonstrated improvements in skin clearance.

  • Long-term effectiveness: Researchers continue examining whether treatment responses remain consistent with continued medication use.

  • Different skin tones: Clinical investigations are providing additional information about treatment effectiveness across diverse skin pigmentation groups.

  • Treatment intervals: The GUIDE clinical trial investigated extended dosing intervals in patients who achieved particularly strong treatment responses. This research provides information about maintaining disease control.

  • Quality of life: Studies assess improvements in itching, discomfort, visible skin symptoms, and the daily challenges associated with psoriasis.

These developments contribute to a broader understanding of targeted biologic therapies and their role in managing chronic inflammatory skin conditions. Research findings also help healthcare professionals evaluate treatment responses and consider individual patient

Related Articles